share_log

Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36

Moomoo 24/7 ·  Mar 15 09:49

Roth MKM analyst Jonathan Aschoff maintains First Wave BioPharma (NASDAQ:FWBI) with a Buy and lowers the price target from $40 to $36.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment